STAP Papers Retracted

Nature issues retractions of the stimulus-triggered acquisition of pluripotency papers and pens an editorial on the controversy surrounding their publication.

By | July 2, 2014

HARUKO OBOKATAAfter months of failed replication attempts, institutional investigations, findings of research misconduct, and several calls for retractions, RIKEN’s Haruko Obokata and her colleagues today (July 2) pulled both of their stimulus-triggered acquisition of pluripotency (STAP) studies. Also retracted was Austin Smith’s News and Views article, which accompanied the two STAP papers when they were published in Nature in January. Smith, a stem-cell researcher from the University of Cambridge, wrote in a Nature notice that his comments were “based on the accuracy and reproducibility of [Obokata and her colleagues’] data.”

In an editorial published today, the journal’s editors said they had verified that STAP was independently replicated in the coauthors’ labs before publishing the studies, and that reviewers of the work “could not have detected the problems that fatally undermined the papers.” Rather, the editors said, Nature was misled by the studies’ authors (specifically, in their contributions statements). “The referees’ rigorous reports quite rightly took on trust what was presented in the papers,” the editors wrote.

“In short: although editors and referees could not have detected the fatal faults in this work, the episode has further highlighted flaws in Nature’s procedures and in the procedures of institutions that publish with us,” the journal’s staff concluded.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech